Background: Conflicting evidence exists regarding potential cardiovascular risks associated with high levels of calcium intake.
C
alcium is a nutrient essential for maintaining bone health. A small proportion of total body calcium (less than 1%) also regulates vascular contraction and vasodilation, muscle function, nerve transmission, intracellular signaling, and hormonal secretion. Vitamin D promotes calcium absorption in the gut and maintains adequate serum calcium and phosphate concentrations, enabling normal bone mineralization and preventing hypocalcemic tetany (1) .
Although adequate calcium and vitamin D intake is critical for maintaining bone health, the role of calcium and vitamin D supplementation in older adults is unclear. Some systematic reviews showed that combined calcium and vitamin D supplementation reduced the risk for fractures in older adults (2, 3) , whereas more recent systematic reviews reported inconsistent effects for fractures across randomized, controlled trials (4, 5) . Experts have raised concerns about a potential effect of a high intake of calcium (with or without vitamin D) from foods and supplements on cardiovascular disease (CVD) outcomes (6 -8). A meta-analysis of both studyand patient-level data from randomized trials showed that calcium with or without vitamin D supplementation increased the risk for myocardial infarction (pooled relative risk, 1.24 [95% CI, 1.07 to 1.45]) and stroke (pooled relative risk, 1.15 [CI, 1.00 to 1.32]) (9, 10). However, a more recent meta-analysis showed that calcium with or without vitamin D supplementation had no statistically significant effects on coronary heart disease events (pooled relative risk, 1.02 [CI, 0.96 to 1.09]) or mortality (pooled relative risk, 1.04 [CI, 0.88 to 1.21]) (11). Many researchers have questioned the strength of the body of evidence linking supplemental calcium intake with CVD risk, noting that cardiovascular outcomes have not been the primary end point of any trial investigating calcium or calcium and vitamin D supplementation to date (12, 13).
To inform a joint position statement from the National Osteoporosis Foundation (NOF) and American Society for Preventive Cardiology, NOF commissioned a focused update and reanalysis of 2 broader evidence reports examining the effects of calcium and vitamin D on a wide range of clinical and intermediate outcomes (5, 14) . This update addresses the effects of calcium intake (from dietary or supplemental sources), alone or in combination with vitamin D, on CVD risk in generally healthy adults. the effects of calcium and vitamin D (alone or in combination) on 17 health outcomes across all life stages that was produced to inform the Institute of Medicine committee charged with updating the dietary reference intake values for calcium and vitamin D (14). In 2014, the Agency for Healthcare Research and Quality commissioned an update of the 2009 evidence report focusing on studies of vitamin D alone or in combination with calcium (5) . The effects of calcium intake (from foods or supplements) alone on CVD were not updated in the 2014 evidence report. Methodological details for the reviews were described in a protocol (15).
Data Sources and Searches
MEDLINE, the Cochrane Central Register of Controlled Trials, and Scopus (including EMBASE) were searched from 2009 to July 2016 for prospective cohort or nested case-control (or case-cohort) studies reporting an association between calcium intake (dietary or supplemental) and risk for incident CVD (cardiac, cerebrovascular, or peripheral vascular events and new hypertension), and for randomized, controlled trials on the effect of increasing calcium intake (by food or supplements) on the same outcomes. Analyses of combinations of calcium and micronutrients other than vitamin D that could not isolate the independent effects of calcium with or without vitamin D were not included. Studies or analyses that did not quantify the amount of calcium in the interventions or exposures also were excluded. The literature search strategy was adapted from the 2009 evidence report (14) but focused on calcium exposures and CVD outcomes. Unpublished data were not sought.
Study Selection
Two reviewers performed abstract and full-text screening to identify peer-reviewed, English-language studies of generally healthy adults in which no more than 20% of participants had known CVD. Studies involving participants with hypertension or elderly populations (>60 years of age) were included, whereas those restricted to pregnant women, persons with diabetes, or those receiving dialysis were excluded. Reference lists of relevant systematic reviews were cross-checked with lists of included studies to ensure that no relevant studies were missed. All cardiovascular event or mortality outcomes (defined by the original authors) were included.
Data Extraction and Risk-of-Bias (Quality) Assessment
All extracted data in the 2009 and 2014 evidence reports (5, 14) are accessible to the public on PubMed and PubMed Health. Relevant data in the 2 evidence reports were extracted from their evidence tables (Appendix C of the evidence reports) and are included in this update. Data from studies published after the 2 evidence reports were extracted by 1 reviewer and confirmed by at least 1 other using the same data extraction form. The risk of bias in randomized, controlled trials and that of observational studies was assessed separately, with the same assessment tools used in the 2009 and 2014 evidence reports (15). However, to be consistent with the current methodology recommended in the Cochrane Handbook for Systematic Reviews of Interventions, we did not assign an overall quality grade for each study in this update (16). Two reviewers did the risk-of-bias assessments independently; disagreements were discussed until consensus was reached.
Data Synthesis
We synthesized trials and cohort studies separately but based our conclusions on the total body of evidence. We did not perform a meta-analysis of trial data, because trials reported outcomes with heterogeneous definitions. For cohort studies, we charted doseresponse curves by using adjusted results and did dose-response metaregressions if 4 or more studies reported analyses of similar exposure-outcome relationships. If more than 1 analysis model was reported in a study, we focused on the model that adjusted for the most potential confounders. Many cohort studies had several analyses reporting different calcium exposures or cardiovascular outcomes of interest. We planned our dose-response metaregressions carefully to ensure that study populations did not overlap in each analysis.
We performed linear and nonlinear dose-response metaregressions to examine the associations between calcium intake levels and the risk for CVD by using a 2-stage hierarchical regression model, implemented in the dosresmeta R package (17, 18). The method, first formalized by Greenland and Longnecker (19), uses estimates of the covariance matrix to account for the within-study correlations across dose levels and incorporates them into the estimation of the linear trend by using generalized least-squares regression. In addition, we applied a method developed by Hamling and colleagues (20) that allowed reconstruction of a table of cell counts ("effective counts") from reported adjusted risk estimates and CIs. We used this method to facilitate dose-response metaregressions and recalculate risk estimates comparing calcium dose categories greater than 1000 mg/d with those less than 1000 mg/d, the recommended dietary allowance for healthy adults (1) . See the Appendix (available at www.annals.org) for details of these procedures.
Analyses were conducted by using SAS, version 9.3 (SAS Institute), and R, version 3.2.5 (R Foundation for Statistical Computing). All P values were 2-tailed, and a P value less than 0.05 was considered statistically significant.
RESULTS

Search Results
We included 4 randomized, controlled trials (in 10 publications [10, 21-29]), 1 nested case-control study (30), and 26 cohort studies (29, 31-55). One publication contained data from a randomized trial and a cohort study (29). Appendix Figure 1 (available at www.annals .org) shows the summary of literature searches and study selection flow for this update.
Randomized, Controlled Trials
Two trials (reported in 8 publications) examined the effects of calcium plus vitamin D supplementation (10, 21-26, 29), whereas 3 looked at the effects of calcium supplementation alone (21, 27, 28). Of these 5 trials, 1 (RECORD [Randomised Evaluation of Calcium or Vitamin D]) was a 2 × 2 factorial design of calcium and vitamin D that contributed to both comparisons (calcium vs. placebo, calcium plus vitamin D vs. placebo) (21). Cardiovascular disease outcomes were secondary end points in all trials (Appendix Table 1 , available at www.annals.org). The overall risk of bias of the trials was low, although concerns were raised regarding poor adherence to the interventions in all trials (Appendix Table 2 , available at www.annals.org). None of the trials reported levels of total calcium intake from dietary and supplemental sources.
Effects of Calcium Plus Vitamin D Supplementation
Overall, 2 trials (WHI [Women's Health Initiative] and RECORD) found no statistically significant differences in risk for CVD events or mortality (except for 2 subgroup analyses) between groups receiving calcium (1000 mg/d) plus vitamin D (400 or 800 IU/d) supplements and those receiving placebo. Individual trial results are shown in Appendix Table 3 (available at www .annals.org).
Several publications analyzed data from the WHI trial (10, 22-26, 29), which randomly assigned 36 282 postmenopausal U.S. women (aged 50 to 79 years) to receive either 1000 mg of calcium plus 400 IU of vitamin D 3 daily or placebo. Six reports examined CVD outcomes at the end of 7 years of supplementation (10, 23-26, 29), and 1 report (22) included CVD outcomes 5 and 12 years after intervention. Outcomes reported in these articles included myocardial infarction, coronary heart disease events or mortality, total heart disease, total CVD, CVD mortality, cerebrovascular death, coronary artery bypass grafting or percutaneous coronary intervention, confirmed angina, hospitalized heart failure, stroke (ischemic, hemorrhagic, or other), transient ischemic attack, and heart failure. Several publications reported post hoc subgroup analyses comparing effects in women using calcium supplements during the trial with those in women not using these supplements, across various age groups or between groups with low and high baseline CVD risk. Only 2 subgroup analyses revealed statistically significant differences between groups. One showed that use of personal calcium supplements altered the effect of calcium and vitamin D on CVD (10). In postmenopausal women receiving calcium supplements, the hazard ratios with calcium and vitamin D were 1.13 to 1.22 for CVD end points. In contrast, among those not taking supplements, the hazard ratios were 0.83 to 1.08. The other subgroup analysis found a lower risk for heart failure with calcium and vitamin D supplementation in postmenopausal women without preexisting heart failure precursors at baseline (hazard ratio, 0.63 [CI, 0.46 to 0.87]) but no statistically significant effect of supplementation in those with heart failure precursors and conditions (hazard ratio, 1.06 [CI, 0.90 to 1.24]) (Appendix Table 3 ) (23). The RECORD trial examined the effects of 3 years of daily supplementation with 1000 mg of calcium, 800 IU of vitamin D 3 , or both on CVD deaths and cerebrovascular disease deaths among 5292 patients (85% female and older than 70 years) recruited from fracture clinics or orthopedic wards in England and Scotland (21). Calcium plus vitamin D supplementation had no statistically significant effect on all vascular disease deaths compared with placebo (risk ratio, 0.99 [CI, 0.82 to 1.20]).
Effects of Calcium Supplementation
Three trials examined the effects of supplementation with calcium alone (doses ranging from 1000 to 1200 mg/d) on various CVD outcomes (21, 27, 28). CAIFOS (Calcium Intake Fracture Outcome Study) from Western Australia examined the effects of 1200 mg of calcium carbonate daily for 5 years on risks for atherosclerotic vascular disease among 1460 elderly women (older than 70 years) recruited from the general population (27). The Auckland calcium study randomly assigned 1471 postmenopausal women (older than 55 years) to receive 5 years of daily supplementation with 1000 mg of calcium citrate or placebo and examined the outcomes of myocardial infarction and stroke 5 years after intervention (28). The RECORD trial (described earlier) reported the effects of calcium supplementation alone on cardiovascular and cerebrovascular deaths (21). None of the studies found a statistically significant effect of calcium supplementation on CVD outcomes (hazard ratios, 0.82 to 1.43) (Appendix Table 3 ).
Prospective Cohort and Nested Case-Control Studies
Twenty-six cohort studies and 1 nested case-control study examined the relationships between calcium intake levels (from foods or supplements) and the risks for CVD outcomes among adults living in the United States (29, 31 Table 4 , available at www.annals.org). Calcium intake was assessed by food-frequency questionnaires in all but 2 cohorts (40, 47). Most studies reported CVD mortality outcomes, assessed by death certificates, International Classification of Diseases codes, medical records, or self-report.
A wide variety of CVD outcomes was reported across the 27 studies, some of which analyzed different sources of calcium separately (Supplement 1, available at www.annals.org). The risk of bias of individual studies ranged from low to moderate (Appendix Table 5 , available at www.annals.org). All studies reported at least 1 analysis of association between calcium intake levels and CVD mortality or stroke.
Relationships Between Calcium Intake Levels and Risks for CVD Mortality
Fifteen studies reported mortality risks (31, 33-35, 37, 39, 41, 42, 44, 46 -49, 53, 54). Individual study results are presented in Figure 1 , which shows analyses examining the associations between total (foods and supplements [top]), dietary (foods only [middle]), and supplemental (supplements only [bottom]) calcium intake levels and the risks for CVD, cardiac, or ischemic heart disease mortality. Total calcium intake levels ranged from 400 to 2400 mg/d, but few data points existed beyond 1600 mg/d. Overall, no consistent dose-response relationships were seen between calcium intake levels and risks for CVD, cardiac, or ischemic heart disease mortality. Overall risk of bias for these studies was moderate, primarily because they did not justify the final statistical models, designate primary outcomes, or report dietary assessment methods completely (Appendix Figure 2 , A through C, available at www.annals.org). Dose-response metaregressions did not detect statistically significant linear or nonlinear relationships between levels of dietary (n = 11) or total (n = 6) calcium intake and the risk for CVD or ischemic heart disease mortality (Table) .
Of the 15 studies, 12 reported data that allowed reanalysis using the effective counts to estimate the risk for CVD mortality, comparing calcium intake levels above with those below 1000 mg/d (reference group) ( Figure 2) . Three studies not included in the reanalysis were done in Asian countries (35, 44, 49); the highest intake levels in these cohorts were less than 1000 mg/d. Overall, the studies showed inconsistent results. Although most results did not reach statistical significance, 1 study (48) showed that dietary calcium intake levels greater than 1000 mg/d (reported mean calcium intake levels in quintile 5 was 1247 mg/d for men and 1101 mg/d for women) were associated with a higher risk for CVD mortality (adjusted hazard ratio, 1.06 [CI, 1.00 to 1.14] for women; adjusted hazard ratio, 1.10 [CI, 1.04 to 1.16] for men). This study also found that supplemental calcium intake (≥1000 mg/d) was associated with an elevated risk for CVD mortality compared with no supplemental intake (adjusted relative risk, 1.20 [CI, 1.05 to 1.36]) and that total calcium intake had a U-shaped association with total CVD mortality in men but not in women. The increased CVD mortality in men was observed at calcium intakes of 1500 mg/d and greater (48). Another study (54) showed that supplemental calcium intake of more than 1000 mg/d was associated with an increase in CVD mortality in men (adjusted relative risk, 1 
Relationships Between Calcium Intake Levels and Risks for Stroke
Twenty cohort studies assessed the association between calcium intake and stroke risk (29, 30, 32, 36, 39 -41, 43-45, 47-55). Individual study results, shown in Figure 3 , display analyses examining the associations between dietary or total calcium intake levels and the risks for total stroke (top) and stroke mortality (bottom). Total calcium intake levels ranged from 200 to 2400 mg/d, and very few data points extended beyond 1600 mg/d. The dose-response relationships between calcium intake levels and risks for total stroke or stroke mortality were highly inconsistent, with some studies showing opposite trends for total stroke risk. The inconsistencies could not be explained by the sex of the study populations. Risk of bias of these studies was moderate, primarily because they did not justify the final statistical models, designate which outcomes were Figure 2 , D and E). Dose-response metaregression analyses did not find statistically significant linear or nonlinear relationships between levels of dietary or total calcium intake and the risk for total stroke (n = 8) or stroke mortality (n = 5) (Table) . Nine studies contributed data to the reanalysis by using the effective counts to estimate the risks for stroke mortality (3 studies) or total stroke (6 studies), comparing calcium intake levels above with those below 1000 mg/d (reference group). Although the results were inconsistent (Figure 4) Data from 5 studies were not sufficient for plotting the dose-response relationships between calcium intake level and risk for stroke (29, 30, 40, 50, 54). Two of these studies reported only analyses of the association between supplemental calcium intake and the risk for stroke (29) or stroke mortality (54) compared with no calcium supplement intake. Neither study (the overall risk of bias was low) found statistically significant associations in men or women (adjusted relative risk, 0.80 to 
DISCUSSION
On the basis of our assessments of internal validity, precision of risk estimates, and consistency of results from randomized trials and prospective cohort studies, we conclude that calcium intake (from either food or supplement sources) at levels within the recommended tolerable upper intake range (2000 to 2500 mg/d) are not associated with CVD risks in generally healthy adults. Although a few trials and cohort studies reported increased risks with higher calcium intake, risk estimates in most of those studies were small (±10% relative risk) and not considered clinically important, even if they were statistically significant.
The mechanisms by which high calcium intake might alter the risk for CVD or stroke among generally healthy adults are unclear. Very high calcium intake is difficult if not impossible to achieve by dietary sources alone. Therefore, the concerns regarding potential adverse cardiovascular risks are related to the use of calcium supplements, which has been associated with increased risk for kidney stones in postmenopausal women (56). Vascular calcification is 1 proposed mechanism for CVD events observed in trials of calcium supplements (9), but available data about calcification of vascular tissues associated with calcium supplementation are derived from persons with impaired renal function (57-59), not from the general population.
Our updated literature search identified several systematic reviews on the same topic, but none synthesized both trials and observational studies. Our findings are consistent with a recent meta-analysis of trials (11) and a meta-analysis of prospective cohort and nested case-control studies (60). However, they are inconsistent with those of several earlier meta-analyses of trials (9, 10) and cohort studies (61-63). Differences in the data synthesis methods may account for the apparent discordant results and conclusions. Earlier metaanalyses of trials did not appraise the risk of bias; some combined trials of calcium supplements used alone with those of calcium plus vitamin D supplements. All 3 earlier meta-analyses of cohort studies (61-63) reported a nonlinear dose-response relationship between calcium intake levels and stroke risks. The doseresponse metaregression methods were unclear in 2 of the meta-analyses (62, 63), and results likely were incorrect because of limitations of the statistical package (glst command) for dose-response meta-analysis implemented in Stata (64). As Liu and colleagues (18) pointed out, glst does not provide solutions for pooling studies with different reference exposure doses, which is the case in all the dose-response meta-analyses of calcium intake and cardiovascular risk. Three metaanalyses of observational studies (60, 62, 63) also included "high-versus-low" or extreme-quantile metaanalyses, which produced uninterpretable pooled results, because the ranges of highest and lowest quantile categories of calcium intake varied substantially across studies. An empirical evaluation of meta-analytic approaches for nutrient and health outcome dose-response data discouraged those that use only data from extreme exposure categories, because the results typically are biased away from the null (65).
Our systematic review and meta-analyses had several limitations. We included only English-language publications; thus, language and publication bias cannot be ruled out. To date, data beyond the tolerable upper intake levels are lacking; thus, the CVD risks at very high calcium intake levels are uncertain. Our metaregressions of cohort studies had moderate risk of bias, potential residual confounding, ecological bias, and imprecise measurement of calcium exposures limited interpretations of data. Ascertainment of total calcium intake levels from foods and supplements was not well-estimated in trials because of adherence issues and was limited by the use of food-frequency questionnaires for assessing dietary exposures in observational studies. Lastly, because different cohort studies adjusted for different sets of confounders, using the risk estimates that adjusted for the most factors in the metaanalyses assumed that the different adjustments across studies would not affect the meta-analytic results-an assumption that we cannot verify without conducting simulation studies.
We believe a trial with sufficient statistical power to detect small differences in adverse cardiovascular outcomes is unlikely to be done. Our search on ClinicalTrials.gov (9 August 2016) identified no ongoing trials designed specifically to address this research question. We recommend future prospective population-based cohort studies that assess total, dietary, and supplemental calcium intake by using validated dietary assessment methodology; ascertain chronic disease outcomes by using standardized outcome measures; and use prospectively developed study protocols, power calculations, and analysis plans.
Systematic review and meta-analysis play an important role in evidence-based medicine. Apparently con- 
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APPENDIX: TECHNICAL DETAILS
Dose-Response Metaregressions
Liu and colleagues (18) described how to use a 2-stage hierarchical metaregression model to estimate the summarized linear and nonlinear dose-response relationship. The model has been implemented in the dosresmeta R package (17). The aim of the first-stage analysis is to estimate for each study the (same) doseresponse association between the adjusted log-relative risks and exposure levels, as described previously by Greenland and Longnecker (19). Their approach is based on constructing an approximate covariance estimate for the adjusted log-odds, -rate, or -risk ratios from a fitted table that conforms to the adjusted logrisk estimates and matches the crude 2 × 2 table margins. In the present analysis, an alternative approach was used. The method by Hamling and colleagues (20) was followed to get estimated cell counts, then the approach of Greenland and Longnecker was used to obtain covariance estimates and the weighted leastsquares estimates. In the second-stage analysis, the study-specific estimates are combined by using the extension of the generalized least-squares method with restricted maximum likelihood estimation to fit the dose-response curves, as described by Berkey and colleagues (68).
To estimate study-specific linear trends, several approximations were made: The reported mean or the midpoint of calcium intake in each category was assigned to the corresponding relative risk. For the open categories, a mean of calcium intake was imputed that was 20% lower for the lowest category threshold or 20% higher for the highest category threshold. If the distributions of person-years or noncases were not provided but analyzed based on quantiles, they were divided equally across the quantiles. For studies that did not use the lowest category of calcium intake as the reference, the method by Hamling and colleagues (20) was used to estimate new relative risks and 95% CIs, setting the lowest category as the new reference. The Hamling group's method is described later in more detail.
Liu and colleagues (18) further described in detail how to construct the design matrix. As the dosespecific relative risks are estimated as contrasts to their reference exposure, the design matrices must be constructed similarly. In the dosresmeta function, this process is done internally by the default option center = TRUE. The argument is particularly important if the reference exposure levels vary across studies or for nonzero reference exposures. In addition, the dose-response model typically does not include the intercept, because the log-relative risk is 0 by definition for the referent value. Nonlinearity was investigated by adopting quadratic models. Statistical heterogeneity was tested using the Cochran Q statistic (considered significant if P < 0.10), and the extent of heterogeneity was quantified with the I 2 index. The R codes used to perform linear and nonlinear dose-response metaregressions are described in Appendix Table 6 (available at www.annals.org). The same models are used to analyze the dose-response relationships between calcium intake levels and risks for CVD mortality or for stroke events or mortality. Analytic datasets for the dose-response metaregressions in Table  1 are in Supplements 2 to 5 (available at www.annals .org). Two "dose" variables for the mean or the midpoint of calcium intake in each category are provided in the Supplements. The variable "dose2" is for sensitivity analysis.
Sensitivity analysis was performed to test the robustness of our dose-response metaregressions by changing the imputed mean of calcium intake for the open categories from 20% to 30% lower or higher for the lowest or highest category, respectively. The results shown in Table 1 were not changed.
Reanalysis Using the Effective Counts
Hamling and colleagues (20) described a method to estimate cell counts-namely the effective counts-of the 2 × 2 table adjusted for confounding, then to estimate the asymptotic correlation between the adjusted log-risk estimates for each exposure level relative to the referent level, from which we can obtain the estimated covariance matrix for these study-specific estimates. The Hamling group's method has been implemented in SAS (available at www.pnlee.co.uk/Software.htm [accessed on 6 September 2016]). These calculations were done study by study, and the effective counts are recorded in Supplement 1.
Importantly, effective counts are assumed to be consistent with the risk estimate, 95% CI, and control rates observed in the individual studies, but the data generated are neither synonymous with nor equivalent to the actual data. These estimates are simply devices used to estimate the underlying, unknown, variancecovariance matrix, which improves model fit and provides better estimates for the SEs and CIs. The numbers themselves have little or no substantive meaning.
For the reanalysis to obtain the risk estimate comparing calcium intake levels above with levels below the recommended daily allowance, we regrouped the exposure categories on the basis of the mean dose value (1000 mg/d or greater vs. less than 1000 mg/d) and calculated adjusted relative risk and its CI by using a 2 × 2 table of the effective counts of events and people at risk in each study. The contrast function also is available in the SAS codes. 97% of participants were followed to study completion.
Calcium alone
At trial closure, 76% of women enrolled were still taking study medications and 59% were taking at least 80% of study pills.
Prentice 
A D E B C
A. Six studies estimated the associations between total calcium intake levels and risks for cardiovascular or ischemic heart disease death. B. Twelve studies estimated the associations between dietary calcium intake levels and risks for cardiovascular or ischemic heart disease death. C. Five prospective cohort studies estimated the associations between supplemental calcium intake levels and risks for cardiovascular or ischemic heart disease death. D. Five studies estimated the associations between total or dietary calcium intake levels and risks for stroke death. E. Ten studies estimated the associations between total or dietary calcium intake levels and risks for total stroke.
